Tango Therapeutics Inc. (TNGX) saw its stock soar 5.10% during intraday trading on Thursday, driven by the company's fourth-quarter financial results that exceeded analyst expectations and the announcement of a new clinical collaboration.

The clinical-stage biotechnology company reported a Q4 net loss of $0.29 per diluted share, narrowing from a $0.32 loss a year earlier and beating the FactSet consensus estimate of a $0.30 loss. The company also reported a strong cash position of $343.1 million as of December 31, 2025, which it expects to fund operations into 2028.

Adding to the positive sentiment, Tango announced a clinical trial collaboration and supply agreement with Erasca Inc. to evaluate Tango's PRMT5 inhibitor vopimetostat in combination with Erasca's pan-RAS molecular glue ERAS-0015. The company also provided optimistic business updates, noting that its lead clinical program, vopimetostat, continues to demonstrate best-in-class potential and is on track to launch its first pivotal study in second-line pancreatic cancer this year.